loader image
Mental Wellness.
For Everyone.
At Tactogen, we are developing a next generation of mental wellness medicines. Psychedelics and other transformative medicines have great promise to heal souls and change lives. Unfortunately, our complex and expensive medical system may keep these benefits out of reach for all but the wealthy. We're working to build a better system. Tactogen is a public benefit corporation whose goal is to make transformative medicines safer, more effective, and more accessible.
We believe the opportunity for non-judgmental reflection and inner peace can fundamentally improve health. Our vision is a world where community wellness is the bedrock of the healthcare system, and where everyone has the tools and support to meet life's challenges.
Co-founder & CeO
Matthew is a neuroscientist and data scientist with over thirty years of experience studying psychedelics. He started Tactogen to ensure the next generation of psychedelic medicines are safe, effective, and accessible to all. Matthew concentrates on IP, product roadmap, regulatory strategy, and scientific community-building.
Co-founder & COO
Luke believes that robust mental health is a planetary priority, and while therapy is helpful, it’s like digging a ditch with a teaspoon compared to psychedelics and talk therapy combined. That’s why he joined Matt to help commercialize safe, legal medicines that increase the connection between people. He concentrates on fundraising and grants, cash flow, corporate development, community partnerships, marketing, ops, team-building, and culture.
Developing IP That Provides Unique Value to Patients
Tactogen is a mission-based and research-driven pharmatech company that uses machine learning and targeted assays to identify promising medicines and new treatments. We seek to understand and leverage the ability of novel small molecules to improve health in a variety of contexts, including anxiety, depression, and stress-related disorders.
February 14, 2022
Tactogen Opposes Ban of Five Tryptamines
Tactogen, in collaboration with Mindstate Design Labs, has formally filed our opposition to a federal proposal to ban five tryptamine derivatives. These compounds do not present significant public health risks. On the contrary, they present significant opportunities to advance science and medicine. 
August 5, 2021
Tactogen in Conversation with the Community
Tactogen CEO Matthew Baggott, Ph.D. had the opportunity to sit down with journalist Erica Rex to discuss our approach to psychedelic medicine. You can read it here. This follows an appearance Matthew made earlier on the Drug Positive podcast of DanceSafe founder Emanuel Sferios.
January 4, 2021
MIT Future of Healthcare and Medicine 2021
“The New Frontiers of Psychedelic Medicine” is one of the most anticipated panels in the history of the MIT Club of Northern California's annual Future of Healthcare and Medicine conference. Held on January 27th, 2021, the panel includes representatives from Compass Pathways, Eleusis Ltd, Journey CoLab, MAPS, and Tactogen.

      © Copyright by Tactogen 2022